跳至主要内容
临床试验/NCT05396612
NCT05396612招募中不适用

Role of the Immune Environment in Response to Therapy in Breast Cancer

Abramson Cancer Center at Penn Medicine1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2022年10月3日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
300
试验地点
1
主要终点
Collecting, processing and archiving breast cancer tumor tissues

研究概览

简要总结

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Collecting, processing and archiving breast cancer tumor tissues

时间窗: Through study completion, average of 2 years

This study will collect and analyze tumor samples from women diagnosed with primary breast cancer. The investigators will dissociate fresh tumor samples and analyze single cell suspensions by flow cytometry. Percentage of dendritic cell and T cell subsets and dendritic cell and T cell activation markers will be compared between breast cancer subtypes (HR+HER2-, HER2+, triple negative). Percentage of dendritic cell and T cell subsets and dendritic cell and T cell activation markers will be compared between HR+HER2- untreated breast cancers compared to HR+HER2- chemotherapy treated breast cancers.

次要结局

  • Associating breast cancer dendritic cell infiltrate with outcome(5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jennifer Zhang

Assistant Professor of Surgery

Abramson Cancer Center at Penn Medicine

研究点 (1)

Loading locations...

相似试验